Search - tctmd.com

Displaying 21 - 40 of 106

Sort: Relevancy | Date

Presentation TCT 2019

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Presenter: Hirotoshi Watanabe

September 28, 2019

Presentation TCT 2019

The Science Behind Xience: From EXCEL to Short DAPT

Presenter: Sripal Bangalore

September 28, 2019

Presentation TCT 2019

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Presenter: Yoshinobu Onuma

September 27, 2019

Presentation TCT 2019

Regulatory Considerations for High Bleeding Risk Patients Undergoing PCI

Presenter: Adrian Magee

September 27, 2019

Presentation TCT 2019

Defining High Bleeding Risk: HBR ARC

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

LM PCI: One Year of DAPT Is Enough, and Sometimes Even Less Is More!

Presenter: Davide Capodanno

September 27, 2019

Presentation TCT 2019

LM PCI: The Default Is Prolonged DAPT (>1 year)!

Presenter: Robert Yeh

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

The Case for Short-Term (1-6 Months) DAPT

Presenter: Anand Prasad

September 27, 2019

Presentation TCT 2019

The Case for Long-Term (1 Year+) DAPT

Presenter: Usman Baber

September 27, 2019

Presentation TCT 2019

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

EVOLVE/ LEADERS Short DAPT Programs

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

COBRA REDUCE / MASTER DAPT

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

XIENCE/ ONYX Short DAPT Programs

Presenter: Mitchell Krucoff

September 27, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

Presentation TCT 2019

MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Presenter: Ken Kozuma

September 26, 2019

Presentation TCT 2019

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Presenter: Ajay Kirtane

September 26, 2019

Advertisement

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

The Science Behind Xience: From EXCEL to Short DAPT

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Regulatory Considerations for High Bleeding Risk Patients Undergoing PCI

Defining High Bleeding Risk: HBR ARC

LM PCI: One Year of DAPT Is Enough, and Sometimes Even Less Is More!

LM PCI: The Default Is Prolonged DAPT (>1 year)!

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

The Case for Short-Term (1-6 Months) DAPT

The Case for Long-Term (1 Year+) DAPT

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

EVOLVE/ LEADERS Short DAPT Programs

COBRA REDUCE / MASTER DAPT

XIENCE/ ONYX Short DAPT Programs

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

MODEL U-SES: A Single-Arm Study of 3-Month DAPT in Patients Treated With a Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content